Humabs ^Company

Humabs is a company that focuses on discovering and developing anti-infective immunotherapies up to clinical proof of concept. They currently have two clinical-stage partnered programs generating significant revenue streams. One of their partnerships is with MedImmune, the global biologics research and development arm of AstraZeneca, for an antibody directed against influenza A virus. This program has concluded the clinical phase 1b/2a and has demonstrated activity against all known subtypes of the influenza A virus. Humabs has also partnered with Novartis for an antibody directed against an undisclosed target, which is currently in phase 2. They also have a portfolio of programs addressing major public health threats such as Ebola, Zika, Rabies, and Dengue.